Axogen, a global leader in surgical solutions for peripheral nerve injuries, has named Michael Dale as its new Chief Executive Officer and a member of the Board of Directors. In the coming nine months, Dale will succeed Karen Zaderej, who will remain in an advisory role. With over 30 years of experience in the management of high-tech medical device companies in a variety of markets, such as cardiovascular, neuromodulation, and diabetes, Dale brings a wealth of knowledge to Axogen. The company's emphasis on sustainable profitability, revenue growth, and commercial expansion is consistent with his appointment.
Axogen is acknowledged as a pioneer in the commercialization and development of technologies for the regeneration and repair of peripheral nerves. The organization is committed to enhancing the quality of life for patients who have experienced sensory or motor function loss as a result of trauma or disease. Axogen remains committed to offering clinically proven and innovative solutions for peripheral nerve repair, thereby assisting surgeons and healthcare providers in the restoration of patient quality of life and nerve function.
